Analysts Issue Forecasts for BCAX FY2026 Earnings

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Investment analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Bicara Therapeutics in a report issued on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt forecasts that the company will post earnings per share of ($1.98) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $13.01 target price on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($2.59) per share.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.28).

Several other research firms have also issued reports on BCAX. Wedbush reaffirmed an “outperform” rating and issued a $30.00 price target on shares of Bicara Therapeutics in a report on Friday, May 23rd. Wall Street Zen downgraded shares of Bicara Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. HC Wainwright decreased their target price on shares of Bicara Therapeutics from $44.00 to $41.00 and set a “buy” rating for the company in a research report on Friday, May 16th. Stifel Nicolaus set a $48.00 price objective on shares of Bicara Therapeutics in a report on Thursday, March 27th. Finally, Wells Fargo & Company raised shares of Bicara Therapeutics from an “underweight” rating to an “equal weight” rating and set a $8.00 price objective for the company in a report on Friday, May 23rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Bicara Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $31.86.

Bicara Therapeutics Stock Down 5.6%

NASDAQ BCAX opened at $11.88 on Tuesday. The firm’s fifty day simple moving average is $12.33 and its two-hundred day simple moving average is $14.01. Bicara Therapeutics has a 12-month low of $7.80 and a 12-month high of $28.09.

Institutional Investors Weigh In On Bicara Therapeutics

Large investors have recently made changes to their positions in the stock. Millennium Management LLC grew its position in shares of Bicara Therapeutics by 28.7% in the fourth quarter. Millennium Management LLC now owns 385,406 shares of the company’s stock valued at $6,714,000 after purchasing an additional 85,847 shares in the last quarter. Northern Trust Corp acquired a new position in Bicara Therapeutics during the fourth quarter worth $2,771,000. Deutsche Bank AG acquired a new position in Bicara Therapeutics during the fourth quarter worth $1,959,000. Legal & General Group Plc acquired a new position in Bicara Therapeutics during the fourth quarter worth $33,000. Finally, Geode Capital Management LLC raised its stake in shares of Bicara Therapeutics by 859.4% in the fourth quarter. Geode Capital Management LLC now owns 466,642 shares of the company’s stock valued at $8,131,000 after acquiring an additional 418,003 shares in the last quarter.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.